Date: 2017-01-24
Type of information: Nomination
Compound: chairman of the board
Company: Anergis (Switzerland)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On January 24, 2017, Anergisannounced the appointment of Dr. Klaus Schollmeier as chairman of its board of directors. Mr. Schollmeier has been a senior executive and advisor to the pharmaceutical and biotech industries for more than 30 years and has senior leadership experience in R&D, Marketing as well as General Management. From 2013 to 2015 Mr. Schollmeier was the CEO of SuppreMol, when the company was sold to Baxalta. From 2004 to 2011 he served as CEO of Santhera, and as Chairman of the Board of Santhera until 2013. Mr. Schollmeier joined Graffinity Pharmaceuticals as CEO in 2003, and in 2004 merged the company with MyoContract to form Santhera. Prior to joining the biotechnology industry in 2003, he was a managing director with the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Before then, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific roles included Head of Oncology/Immunology Research at BASF’s central laboratories in Ludwigshafen, Germany, and, from 1989 to 1993, Senior Director of Biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA. He was also a general manager at BASF Pharma Netherlands from 1996 to 1998, and subsequently Vice President and General Manager for Western Europe.
Financial terms:
Latest news:
